{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T07:24:17Z","timestamp":1744183457677,"version":"3.37.3"},"reference-count":14,"publisher":"Oxford University Press (OUP)","issue":"21","license":[{"start":{"date-parts":[[2019,5,9]],"date-time":"2019-05-09T00:00:00Z","timestamp":1557360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly & Co.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Accelerating Medicines Partnership-Alzheimer\u2019s Disease"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Summary<\/jats:title>\n                  <jats:p>We present software to characterize and rank potential therapeutic (drug) targets with data from public databases and present it in a user-friendly format. By understanding potential obstacles to drug development through the gathering and understanding of this information, combined with robust approaches to target validation to generate therapeutic hypotheses, this approach may provide high quality targets, leading the process of drug development to become more efficient and cost-effective.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Availability and implementation<\/jats:title>\n                  <jats:p>The information we gather on potential targets concerns small-molecule druggability (ligandability), suitability for large-molecule approaches (e.g. antibodies) or new modalities (e.g. antisense oligonucleotides, siRNA or PROTAC), feasibility (availability of resources such as assays and biological knowledge) and potential safety risks (adverse tissue-wise expression, deleterious phenotypes). This information can be termed \u2018tractability\u2019. We provide visualization tools to understand its components. TractaViewer is available from https:\/\/github.com\/NeilPearson-Lilly\/TractaViewer<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Supplementary information<\/jats:title>\n                  <jats:p>Supplementary data are available at Bioinformatics online.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/bioinformatics\/btz270","type":"journal-article","created":{"date-parts":[[2019,4,23]],"date-time":"2019-04-23T11:27:32Z","timestamp":1556018852000},"page":"4509-4510","source":"Crossref","is-referenced-by-count":5,"title":["TractaViewer: a genome-wide tool for preliminary assessment of therapeutic target druggability"],"prefix":"10.1093","volume":"35","author":[{"given":"Neil","family":"Pearson","sequence":"first","affiliation":[{"name":"Eli Lilly & Co. Ltd, Erl Wood Manor , Windlesham, UK"}]},{"given":"Karim","family":"Malki","sequence":"additional","affiliation":[{"name":"Eli Lilly & Co. Ltd, Erl Wood Manor , Windlesham, UK"}]},{"given":"David","family":"Evans","sequence":"additional","affiliation":[{"name":"Eli Lilly & Co. Ltd, Erl Wood Manor , Windlesham, UK"}]},{"given":"Lewis","family":"Vidler","sequence":"additional","affiliation":[{"name":"Eli Lilly & Co. Ltd, Erl Wood Manor , Windlesham, UK"}]},{"given":"Cara","family":"Ruble","sequence":"additional","affiliation":[{"name":"Eli Lilly & Co, Corporate Centre , Indianapolis, IN, USA"}]},{"given":"James","family":"Scherschel","sequence":"additional","affiliation":[{"name":"Eli Lilly & Co, Corporate Centre , Indianapolis, IN, USA"}]},{"given":"Brian","family":"Eastwood","sequence":"additional","affiliation":[{"name":"Eli Lilly & Co. Ltd, Erl Wood Manor , Windlesham, UK"}]},{"given":"David A","family":"Collier","sequence":"additional","affiliation":[{"name":"Eli Lilly & Co. Ltd, Erl Wood Manor , Windlesham, UK"}]}],"member":"286","published-online":{"date-parts":[[2019,5,9]]},"reference":[{"key":"2023062712471987000_btz270-B1","first-page":"D940\u2013D944","article-title":"OGEE v2: an update of the online gene essentiality database with special focus on differentially essential genes in human cancer cell lines","author":"Chen","year":"2017","journal-title":"Nucleic Acids Res"},{"key":"2023062712471987000_btz270-B2","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1093\/nar\/gku1071","article-title":"Genenames.org: the HGNC resources in 2015","volume":"43","author":"Gray","year":"2014","journal-title":"Nucleic Acids Res"},{"key":"2023062712471987000_btz270-B3","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1038\/nmeth.2689","article-title":"DGIdb: mining the druggable genome","volume":"12","author":"Griffith","year":"2013","journal-title":"Nat. Methods"},{"key":"2023062712471987000_btz270-B4","doi-asserted-by":"crossref","DOI":"10.1093\/database\/bar030","article-title":"Ensembl BioMarts: a hub for data retrieval across taxonomic space","volume":"2011","author":"Kinsella","year":"2011","journal-title":"Database"},{"key":"2023062712471987000_btz270-B5","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1093\/nar\/gkw1039","article-title":"The human phenotype ontology in 2017","volume":"45","author":"K\u00f6hler","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"2023062712471987000_btz270-B6","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1093\/nar\/gkw1055","article-title":"Open Targets: a platform for therapeutic target identification and validation","volume":"45","author":"Koscielny","year":"2016","journal-title":"Nucleic Acids Research"},{"key":"2023062712471987000_btz270-B7","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nature12912","article-title":"Discovery and saturation analysis of cancer genes across 21 tumour types","volume":"7484","author":"Lawrence","year":"2014","journal-title":"Nature"},{"key":"2023062712471987000_btz270-B8","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1093\/nar\/gkw1072","article-title":"Pharos: collating protein information to shed light on the druggable genome","volume":"45","author":"Nguyen","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"2023062712471987000_btz270-B9","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nrd.2018.14","article-title":"Unexplored therapeutic opportunities in the human genome","volume":"17","author":"Oprea","year":"2018","journal-title":"Nat. Rev. Drug Discov"},{"key":"2023062712471987000_btz270-B10","doi-asserted-by":"crossref","first-page":"203.","DOI":"10.1038\/nrd3078","article-title":"How to improve R&D productivity: the pharmaceutical industry\u2019s grand challenge","volume":"9","author":"Paul","year":"2010","journal-title":"Nat. Rev. Drug Discov"},{"key":"2023062712471987000_btz270-B11","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/path.2440","article-title":"The Human Protein Atlas\u2014a tool for pathology","volume":"216","author":"Pont\u00e9n","year":"2008","journal-title":"J. Pathol"},{"key":"2023062712471987000_btz270-B12","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.drudis.2016.02.004","article-title":"Filtering promiscuous compounds in early drug discovery: is it a good idea?","volume":"21","author":"Senger","year":"2016","journal-title":"Drug Discov. Today"},{"key":"2023062712471987000_btz270-B13","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/nar\/gkv1192","article-title":"WITHDRAWN\u2014a resource for withdrawn and discontinued drugs","volume":"44","author":"Siramshetty","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"2023062712471987000_btz270-B14","doi-asserted-by":"crossref","first-page":"2650.","DOI":"10.1038\/srep02650","article-title":"Comprehensive identification of mutational cancer driver genes across 12 tumor types","volume":"3","author":"Tamborero","year":"2013","journal-title":"Sci. Rep"}],"container-title":["Bioinformatics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/bioinformatics\/advance-article-pdf\/doi\/10.1093\/bioinformatics\/btz270\/28670738\/btz270.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bioinformatics\/article-pdf\/35\/21\/4509\/50721618\/bioinformatics_35_21_4509.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bioinformatics\/article-pdf\/35\/21\/4509\/50721618\/bioinformatics_35_21_4509.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,27]],"date-time":"2023-06-27T12:47:42Z","timestamp":1687870062000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bioinformatics\/article\/35\/21\/4509\/5487388"}},"subtitle":[],"editor":[{"given":"Jonathan","family":"Wren","sequence":"additional","affiliation":[]}],"short-title":[],"issued":{"date-parts":[[2019,5,9]]},"references-count":14,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2019,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/bioinformatics\/btz270","relation":{},"ISSN":["1367-4803","1367-4811"],"issn-type":[{"type":"print","value":"1367-4803"},{"type":"electronic","value":"1367-4811"}],"subject":[],"published-other":{"date-parts":[[2019,11,1]]},"published":{"date-parts":[[2019,5,9]]}}}